Adma Biologics

ADMANasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$2.936 B

$13.24 +26.29%

Close of 6 Nov 2026

As of 6 Nov 2026, Adma Biologics (ADMA) has a market capitalization of $2.94B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$510.2M

#1879 by revenue

Earnings

$146.9M

#1134 by earnings

Shares outstanding

221,854,389

Latest filing cover page

P/E ratio

20.0

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#27Tarsus PharmaceuticalsTARS$3.33B
#28Denali TherapeuticsDNLI$3.16B
#29Adma BiologicsADMA$2.94B
#30Beam TherapeuticsBEAM$2.68B
#31VericelVCEL$2.65B

What if Adma Biologics were worth as much as…

Open the what-if tool →

Gold $28.2T

$127,276.61

Per share 9,617× higher

Bitcoin $1.53T

$6,886.72

Per share 520× higher

Apple $5.02T

$22,608.44

Per share 1,708× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for Adma Biologics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.